Abstract
Background
The Epstein–Barr virus (EBV) infection status in patients with inflammatory bowel disease (IBD), particularly those using thiopurines, may be associated with the risk of lymphoproliferative disorder and hemophagocytic lymphohistiocytosis. This was the first multicenter survey of EBV infection in Japanese patients with IBD. Factors related to the EBV infection status were also investigated.
Methods
Five tertiary institutions in Japan participated in this study to examine pediatric and adult patients with IBD. Serum EBV anti-viral capsid antigen (VCA) IgG, EBV anti-VCA IgM, and anti-EBV nuclear antigen–antibody were measured in 495 patients with IBD. The patients’ information was obtained from their medical records. Prior EBV infection was defined as anti-VCA IgM negativity and anti-VCA IgG positivity (UMIN000033004).
Results
The patients’ median age was 25 years (range 0–92 years). Of the 495 patients, nine were anti-VCA IgM-positive and 354 were anti-VCA IgG-positive (seroprevalence: 72.8%). The proportion of patients with prior EBV infection was 0% for those aged < 5 years, < 60% for those aged < 30 years, and > 90% for those aged > 30 years. The proportion of EBV-uninfected patients using thiopurines was 28.4% (52/183) for all patients and 51.8% (44/85) for pediatric patients. Age was significantly associated with anti-VCA IgG seropositivity (p < 0.01, odds ratio: 0.902, 95% confidence interval: 0.880–0.925). No cases of lymphoproliferative disorder, hemophagocytic lymphohistiocytosis, or chronic active EBV infection were reported.
Conclusions
Approximately 30% of Japanese patients with IBD were EBV-uninfected, including those using thiopurines. Age was a significant factor for anti-VCA IgG seropositivity.
Similar content being viewed by others
Abbreviations
- CD:
-
Crohn’s disease
- EBNA:
-
Epstein–Barr virus nuclear antigen
- EBV:
-
Epstein–Barr virus
- HLH:
-
Hemophagocytic lymphohistiocytosis
- IBD:
-
Inflammatory bowel disease
- IBDU:
-
Inflammatory bowel disease unclassified
- LPD:
-
Lymphoproliferative disorder
- UC:
-
Ulcerative colitis
- VCA:
-
Viral capsid antigen
References
Odumade OA, Hogquist KA, Balfour HH Jr. Progress and problems in understanding and managing primary Epstein-Barr virus infections. Clin Microbiol Rev. 2011;24:193–209.
Cohen JI. Epstein-Barr virus infection. N Engl J Med. 2000;343:481–92.
Chan HC, Ng SC. Emerging biologics in inflammatory bowel disease. J Gastroenterol. 2017;52:141–50.
Tsai L, Ma C, Dulai PS, et al. Contemporary risk of surgery in patients with ulcerative colitis and Crohn’s disease: a meta-analysis of population-based cohorts. Clin Gastroenterol Hepatol. 2020. https://doi.org/10.1016/j.cgh.2020.10.039.
Annese V, Beaugerie L, Egan L, et al. European evidence-based consensus: inflammatory bowel disease and malignancies. J Crohns Colitis. 2015;9:945–65.
Beaugerie L, Brousse N, Bouvier AM, CESAME Study Group, et al. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet. 2009;374:1617–25.
Herrinton LJ, Liu L, Weng X, et al. Role of thiopurine and anti-TNF therapy in lymphoma in inflammatory bowel disease. Am J Gastroenterol. 2011;106:2146–53.
Chupin A, Perduca V, Meyer A, et al. Systematic review with meta-analysis: comparative risk of lymphoma with anti-tumour necrosis factor agents and/or thiopurines in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2020;52:1289–97.
Wisniewski A, Kirchgesner J, Seksik P, et al. Increased incidence of systemic serious viral infections in patients with inflammatory bowel disease associates with active disease and use of thiopurines. United Eur Gastroenterol J. 2020;8:303–13.
Posthuma EF, Westendorp RG, van der Sluys VA, et al. Fatal infectious mononucleosis: a severe complication in the treatment of Crohn’s disease with azathioprine. Gut. 1995;36:311–3.
Biank VF, Sheth MK, Talano J, et al. Association of Crohn’s disease, thiopurines, and primary Epstein-Barr virus infection with hemophagocytic lymphohistiocytosis. J Pediatr. 2011;159:808–12.
Fries W, Cottone M, Cascio A. Systematic review: macrophage activation syndrome in inflammatory bowel disease. Aliment Pharmacol Ther. 2013;37:1033–45.
Hyams JS, Dubinsky MC, Baldassano RN, et al. Infliximab is not associated with increased risk of malignancy or hemophagocytic lymphohistiocytosis in pediatric patients with inflammatory bowel disease. Gastroenterology. 2017;152:1901–14.
Fukata N, Okazaki K, Omiya M, et al. Hematologic malignancies in the Japanese patients with inflammatory bowel disease. J Gastroenterol. 2014;49:1299–306.
Kobayashi T, Uda A, Udagawa E, et al. Lack of increased risk of lymphoma by thiopurines or biologics in Japanese patients with inflammatory bowel disease: a large-scale administrative database analysis. J Crohns Colitis. 2020;14:617–23.
Rahier JF, Magro F, Abreu C, et al. Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis. 2014;8:443–68.
Winter JR, Taylor GS, Thomas OG, et al. Predictors of Epstein-Barr virus serostatus in young people in England. BMC Infect Dis. 2019;19:1007.
Takeuchi K, Tanaka-Taya K, Kazuyama Y, et al. Prevalence of Epstein-Barr virus in Japan: trends and future prediction. Pathol Int. 2006;56:112–6.
Condon LM, Cederberg LE, Rabinovitch MD, et al. Age-specific prevalence of Epstein-Barr virus infection among Minnesota children: effects of race/ethnicity and family environment. Clin Infect Dis. 2014;59:501–8.
Crawford DH, Macsween KF, Higgins CD, et al. A cohort study among university students: identification of risk factors for Epstein-Barr virus seroconversion and infectious mononucleosis. Clin Infect Dis. 2006;43:276–82.
Chen CY, Huang KY, Shen JH, et al. A large-scale seroprevalence of Epstein-Barr virus in Taiwan. PLoS ONE. 2015;10:e0115836.
Love KA, Henderson P, Garrick V, et al. Letter: Epstein-Barr virus status may be especially important in paediatric IBD populations. Aliment Pharmacol Ther. 2014;39:231–2.
Hradsky O, Copova I, Zarubova K, et al. Seroprevalence of Epstein-Barr virus, cytomegalovirus, and polyomaviruses in children with inflammatory bowel disease. Dig Dis Sci. 2015;60:3399–407.
Linton MS, Kroeker K, Fedorak D, et al. Prevalence of Epstein-Barr virus in a population of patients with inflammatory bowel disease: a prospective cohort study. Aliment Pharmacol Ther. 2013;38:1248–54.
de Francisco R, Castaño-García A, Martínez-González S, et al. Impact of Epstein-Barr virus serological status on clinical outcomes in adult patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2018;48:723–30.
Gordon J, Ramaswami A, Beuttler M, et al. EBV status and thiopurine use in pediatric IBD. J Pediatr Gastroenterol Nutr. 2016;62:711–4.
El-Matary W. Routine testing for EBV status in children with inflammatory bowel disease: are we overreacting? Inflamm Bowel Dis. 2020;26:e20.
Hans AK, Scott FI. Editorial: which inflammatory bowel disease patients should be screened for Epstein-Barr virus infection? Aliment Pharmacol Ther. 2018;48:1158–9.
Acknowledgements
We thank Traci Raley, MS, ELS and Angela Morben, DVM, ELS, from Edanz Group (https://jp.edanz.com/ac) for editing a draft of this manuscript.
Funding
This work was supported in part by grants from the Japan Sciences Research Grant for Research on Intractable Diseases (Japanese Inflammatory Bowel Disease Research Group) affiliated with the Japan Ministry of Health, Labour and Welfare.
Author information
Authors and Affiliations
Contributions
Concept and design of the study: TH, MMi, HS, KA, II, HN, and TS; acquisition of data: TH, MMi, HS, DS, TK, DH, MY, KA, II, HN, and TS; analysis and interpretation of data: TH, MMi, JM, MMa, KA, II, HN, and TS; drafting of the manuscript: MMi, TH, JM, and MMa; critical revision of the manuscript for important intellectual content: KA, II, HN, and TS; statistical analyses: JM; study supervision: TH, KA, II, HN, and TS.
Corresponding author
Ethics declarations
Conflict of interest
Tadakazu Hisamatsu has performed joint research with Alfresa Pharma Co., Ltd. and EA Pharma Co., Ltd.; received grant support from Mitsubishi Tanabe Pharma Corporation, EA Pharma Co., Ltd., AbbVie GK, JIMRO Co., Ltd., Zeria Pharmaceutical Co., Ltd., Daiichi-Sankyo, Kyorin Pharmaceutical Co., Ltd., Nippon Kayaku Co., Ltd., Takeda Pharmaceutical Co., Ltd., Pfizer Inc., and Mochida Pharmaceutical Co., Ltd.; and received consulting and lecture fees from Mitsubishi Tanabe Pharma Corporation, AbbVie GK, Celgene K.K., EA Pharma Co., Ltd., Kyorin Pharmaceutical Co. Ltd., JIMRO Co., Janssen Pharmaceutical K.K., Mochida Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd., and Pfizer Inc. Jun Miyoshi received lecture fees from JIMRO Co. and Takeda Pharmaceutical Co., Ltd. Minoru Matsuura received commercial research funding from AbbVie GK, Mitsubishi Tanabe Pharma Corporation, EA Pharma Co., Ltd., Mochida Pharmaceutical Co., Ltd., Nippon Kayaku Co., Ltd., and JIMRO Co. and received lecture fees from Janssen Pharmaceutical K.K., Mitsubishi Tanabe Pharma Corporation, AbbVie GK, Takeda Pharmaceutical Co., Ltd., Kyorin Pharmaceutical Co., Ltd., Mochida Pharmaceutical Co., Ltd., Viatris Inc., Sandoz K.K., JIMRO Co., Nippon Kayaku Co., Ltd., Kissei Pharmaceutical Co., Ltd., EA Pharma Co., Ltd., and Zeria Pharmaceutical Co., Ltd. Katsuhiro Arai received grant support from Nippon Kayaku Co., Ltd. and received consulting and lecture fees from Mitsubishi Tanabe Pharma Corporation, Janssen Pharmaceutical K.K., EA Pharma Co., Ltd., AbbVie GK, Zeria Pharmaceutical Co., Ltd., Kyorin Pharmaceutical Co., Ltd., Nippon Kayaku Co., Ltd., Takeda Pharmaceutical Co., Ltd., Alfresa Pharma Corporation, Eli Lilly Japan K.K., and Nobelpharma Co., Ltd. Hirotaka Shimizu received grant support from Nippon Kayaku Co., Ltd. Hiroshi Nakase received honoraria from Mitsubishi Tanabe Pharma Corporation, Mochida Pharmaceutical Co., Ltd., Janssen Pharmaceutical K.K., and Abbvie GK and commercial research funding from Hoya Group Pentax Medical, Boehringer Ingelheim GmbH, and Daticho-Sankyo Co., Ltd. Toshiaki Shimizu received research grants from Otsuka Pharmaceutical Co., Ltd., Japan Blood Products Organization, EA Pharma Co., Ltd., and Kissei Pharmaceutical Co., Ltd. Miki Miura, Daisuke Saito, Yoshida Masashi, Takahiro Kudo, Daisuke Hirayama, Masashi Yoshida, and Itaru Iwama have no conflicts of interest.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
Below is the link to the electronic supplementary material.
535_2021_1832_MOESM2_ESM.pptx
Supplementary file2 Supplemental Fig. 1 Flowchart of patients in this study. UC ulcerative colitis; CD Crohn’s disease; IBDU inflammatory bowel disease unclassified; VCA viral capsid antigen (PPTX 42 KB)
Rights and permissions
About this article
Cite this article
Miura, M., Shimizu, H., Saito, D. et al. Multicenter, cross-sectional, observational study on Epstein–Barr viral infection status and thiopurine use by age group in patients with inflammatory bowel disease in Japan (EBISU study). J Gastroenterol 56, 1080–1091 (2021). https://doi.org/10.1007/s00535-021-01832-w
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00535-021-01832-w